Mid-cap stocks fell lately, but a list of the most oversold names by Relative Strength Index points to possible rebound candidates across health care, media, food, biotech, and real estate sectors.

Management projected full-year 2025 revenue of $5.6 billion to $5.65 billion, adjusted EBITDA of $468 million to $473 million, and adjusted EPS of $1.68 to $1.72. Sethna said, "We continue to expect ...

Management expects meaningful pressure from STELARA biosimilar conversions — a ~160-basis-point revenue drag in 2025 and an anticipated ~400-basis-point revenue growth headwind plus a $25–35 million ...

Jefferies has upgraded Option Care Health (NASDAQ:OPCH) to buy from hold, citing removal of an overhang related to pricing adjustments for the drug Stelara. The investment bank said it had downgraded ...

Option Care Health (NASDAQ:OPCH) sharers fell over 4% on Monday, after Goldman Sachs downgraded the company to Neutral from Buy. The brokerage, which set a PT of $27 on the stock, said it had ...

Previous title: Executive vice president and chief financial officer, Littelfuse New title: Executive vice president and chief financial officer, Option Care Health Sethna will assume the head finance ...

Option Care Health, Inc. reported strong financial results for the fourth quarter and full year of 2024, highlighting a 19.7% increase in net revenue to $1.35 billion in Q4 compared to the previous ...

BANNOCKBURN, Ill. (AP) — BANNOCKBURN, Ill. (AP) — Option Care Health, Inc. (OPCH) on Tuesday reported fourth-quarter profit of $58.5 million. On a per-share basis, the Bannockburn, Illinois-based ...

Option Care Enterprises, Inc., one of the nation’s leading providers of home and alternate treatment site infusion therapy services, has earned URAC Specialty Pharmacy accreditation with a perfect ...